行情

AYTU

AYTU

Aytu BioScience
NASDAQ

实时行情|Nasdaq Last Sale

0.7390
-0.0610
-7.63%
盘后: 0.7620 +0.023 +3.11% 17:41 12/06 EST
开盘
0.7800
昨收
0.8000
最高
0.8200
最低
0.7100
成交量
28.25万
成交额
--
52周最高
2.610
52周最低
0.6800
市值
1,532.17万
市盈率(TTM)
-0.2855
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AYTU 新闻

  • Edited Transcript of AYTU earnings conference call or presentation 14-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1天前
  • MiOXSYS Male Infertility Test Will be Featured in Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine
  • ACCESSWIRE.1天前
  • Aytu BioScience to Present at LD Micro 12th Annual Main Event Investor Conference on December 11, 2019
  • ACCESSWIRE.3天前
  • 兴业银行:美国国债收益率或将因衰退风险而跌至1.2%
  • 新浪财经综合.3天前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
+0.32%

热门股票

名称
价格
涨跌幅

AYTU 简况

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
展开

Webull提供Aytu Bioscience Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。